Bhushan Akshikar, Managing Director of GSK India, said the company is committed to making these therapies accessible through a tiered pricing strategy and a comprehensive patient support program ...

Endometrial cancer risk is rising, especially among premenopausal women, with diet and lifestyle factors playing a central ...

GlaxoSmithKline Pharmaceuticals said it is bringing in Jemperli and Zejula to India, marking its re-entry into the cancer ...

At around 2.14 PM, GSK Pharma was trading 0.28% higher at ₹2,806.70 per piece, against the previous close of ₹2,798.80 on NSE.

GlaxoSmithKline Pharmaceuticals on Monday said it has made a foray into the oncology segment, bringing precision therapies ...

GlaxoSmithKline Pharmaceuticals has launched Jemperli and Zejula in India, pioneering precision therapies for gynaecological ...

GSK enters oncology with Jemperli & Zejula for gynaecological cancers in India. Advanced therapies address unmet needs in ...

Jemperli is the first and only approved programmed death receptor-1 (PD-1) immunotherapy for the second-line treatment of ...

GlaxoSmithKline (GSK) has announced its foray into oncology in India with the launch of Jemperli (dostarlimab) and Zejula (niraparib). Jemperli is the first and only approved PD-1 immunotherapy for ...

GlaxoSmithKline (GSK) on Monday announced its foray into the Indian oncology market with the launch of two precision ...